Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHM-2101 in Relapsed or Refractory Gastrointestinal Cancers
NCT06055439Phase 2Active, not recruiting
- Sponsor
- Chimeric Therapeutics
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of CHM-2101 in Neuroendocrine Neoplasm (NEN), colorectal cancer (CRC), gastric cancer (GC), sponsored by Chimeric Therapeutics. Started May 2024; status: active, not recruiting.
02
Drugs
CHM-2101
03
Conditions
Neuroendocrine Neoplasm (NEN)colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT06055439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055439.